In response to the COVID-19 pandemic, the biopharmaceutical industry has leapt into action to better understand the disease and develop suitable vaccines and therapies. Trajan Scientific and Medical and Synexa Life Sciences have developed and validated an innovative, market-leading SARS-CoV-2 serology assay, available for high-throughput clinical research applications, using Trajan's advanced precision microsampling technology to expedite therapy and vaccine development as well as large-scale screening, sero-surveillance and post-market surveillance initiatives.
With hemaPEN’s® innovative, easy-to-use design and microsampling technology, large scale screening and sero-surveillance studies post-vaccine roll out can be conducted safely and efficiently, while maintaining social distancing protocols and maintaining patient-centricity, comfort and convenience.
Combining this technology with Synexa’s innovative, market-leading SARS-CoV-2 serology assay - a versatile technology capable of detecting IgG, IgM, IgA and nAb antibody response, as well as their semi-quantification without the need for titration - has yielded a highly competitive and flexible assay, suitable across a wide range of applications.
Through this collaboration, Trajan and Synexa have developed a powerful platform to enable vaccine programs with more convenience and comfort for the patient, while retaining high quality data for understanding the safety and efficacy of vaccines.
If you would like more information about our product and service offering to assist and support your vaccine program, please contact us.
Download
Brochure - SARS-CoV-2 serology testing
Related news
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC's Analyst
More information
www.hemapen.com
Media contact information
Trajan Scientific and Medical
Tel: +44 (0) 1908 568 844
media@trajanscimed.com
